Keloids - Pipeline Insight, 2024

This “Keloids - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Keloids Understanding

Keloids: Overview

Keloids also known as keloid scars are abnormal proliferation of fibrous tissues (scar tissue) formed over a healing wound. Keloids can grow much larger than a usual wound and are most commonly found on chest, ears, and cheeks. However, they can develop at any site. Although keloids are not harmful but can cause cosmetic concerns. Any skin injury can lead to keloid formation such as acne scars, ear piercing, scratching, and surgical incision site. Keloids affect both sexes equally mainly those with darker skin tone.Symptoms of Keloids include raised red lumpy and ridged skin, and itching.

Keloids - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Keloids R&D. The therapies under development are focused on novel approaches to treat/improve Keloids.

Keloids Emerging Drugs Chapters

This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Keloids Emerging Drugs

MRG-201: Viridian Therapeutics Viridian’s lead drug candidate, MRG-201 is developed to mimic the activity of miR-29 molecule which reduce the expression of proteins, and collagen associated with scar formation. The drug molecule has demonstrated good efficacy results in its phase I trial.

STP-705: Sirnaomics Sinaomics “breakthrough” drug STP-705 is currently being evaluated for the treatment of keloids and has demonstrated good safety and efficacy profile in its pre-clinical trials. The drug is a si RNA that knock down the COX-2 gene andTBFß1expression.

Keloids: Therapeutic Assessment

This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Keloids

There are approx. 5+ key companies which are developing the therapies for Keloids. The companies which have their Keloids drug candidates in the most advanced stage, i.e. phase II include, Viridian Therapeutics and others.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Keloids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Keloids: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.

Keloids Report Insights

• Keloids Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Keloids Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Keloids drugs?
• How many Keloids drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloids?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Keloids therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Keloids and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Viridian Therapeutics
• Sirnaomics
• Lemonex

Key Products

• MRG-201
• STP-705
• LEMS401